Adjuvant immunotherapy for cervical cancer. Two randomized controlled studies using OK-432 or sizofiran.
Okamura
K
K
Department of Obstetrics and Gynecology, Tohoku University School of Medicine, 1-1 Seiryo machi, Sendai 980, Japan.
Yajima
A
A
Noda
K
K
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D009367:Neoplasm Staging; D010844:Picibanil / Q000008:administration & dosage; D016032:Randomized Controlled Trials as Topic; D012566:Sizofiran / Q000008:administration & dosage; D016019:Survival Analysis; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology
D010844:Picibanil; D012566:Sizofiran